NSABP FB-12
NSABP FB-12
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant ACT+Trastuzumab and Pertuzumab in Early Stage HER-2 Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER-2 Signaling Transduction
Protocol Chair: Eleftherios Mamounas, MD, MPH
Protocol Officer: Priya Rastogi, MD
Patient Population:
Patients with HER2-negative breast cancer with abnormal HER2 signaling
Target Accrual: 54 patients
Status: Recruiting
ClinicialTrials.gov Identifier: NCT03412643
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant ACT+Trastuzumab and Pertuzumab in Early Stage HER-2 Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER-2 Signaling Transduction
Protocol Chair: Eleftherios Mamounas, MD, MPH
Protocol Officer: Priya Rastogi, MD
Patient Population:
Patients with HER2-negative breast cancer with abnormal HER2 signaling
Target Accrual: 54 patients
Status: Recruiting
ClinicialTrials.gov Identifier: NCT03412643